NCT06827613View on ClinicalTrials.gov

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Interventions
DRUG

STAR0602

solution, intravenous infusion

DRUG

Sacituzumab Govitecan (SG)

intravenous infusion, 10mg/kg

Trial Locations (8)

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

43212

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

78229

RECRUITING

UT Health San Antonio MD Anderson Cancer Center, San Antonio

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

90095

RECRUITING

UCLA Health, Los Angeles

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

V5Z 1K1

RECRUITING

BC Cancer, Vancouver

M5G 2C4

RECRUITING

Princess Margaret Cancer Centre, Toronto

Sponsors
All Listed Sponsors
lead

Marengo Therapeutics, Inc.

INDUSTRY

NCT06827613 - A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter